Exelixis | EXEL - Sales Revenues


Exelixis reported $610.8M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Genmab DKK 1.06B 36M Dec/2025
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sanofi EUR 12.14B 65M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026